Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI

Wight, Joel C., Chong, Geoffrey, Grigg, Andrew P., and Hawkes, Eliza A. (2018) Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Reviews, 32 (5). pp. 400-415.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website:


Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with variable outcomes. Despite the majority of patients being cured with combination chemoimmunotherapy, up to 30% eventually succumb to the disease. Until recently, baseline prognostic assessment has centred on the International Prognostic Index (IPI), although this index is yet to impact strongly on treatment choice. Molecular features such as cell of origin, MYC and BCL-2 genetic alterations and protein overexpression were identified over a decade ago, yet their prognostic value is still not fully elucidated. Adding complexity are the plethora of new clinical, biological and molecular prognostic markers described in the recent literature, most of which lack independent validation, likely act as surrogate markers for those already in common use and have yet to substantially impact on therapeutic decision making. This review comprehensively assesses the value of individual prognostic markers in the clinical setting and their potential to predict response to novel agents, and ways to optimise their use in future research.

Item ID: 77893
Item Type: Article (Research - C1)
ISSN: 1532-1681
Copyright Information: © 2018 Elsevier Ltd. All rights reserved.
Date Deposited: 14 Mar 2023 00:15
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3211 Oncology and carcinogenesis > 321106 Haematological tumours @ 100%
SEO Codes: 20 HEALTH > 2001 Clinical health > 200105 Treatment of human diseases and conditions @ 100%
Downloads: Total: 1
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page